title: Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
abstract: OBJECTIVE
  Macrophage activating factor (MAF)-based immunotherapy has a wide application for use in treating many diseases via macrophage activation. Sonodynamic therapy (SDT) using low-intensity ultrasound and tumor treating field (TTF) therapy are novel therapeutic modalities. SDT is usually combined with ozone therapy to improve local hypoxia within the tumor environment.
  
  
  METHODS
  We treated a 77-year-old male diagnosed with non-small cell lung cancer ((NSCLC) stage 3B) using second-generation serum GcMAF and oral colostrum MAF-based immunotherapy combined with SDT, TTF and ozone therapies.
  
  
  RESULTS
  This case report demonstrates that GcMAF, oral colostrum MAF, SDT, TTF and ozone therapy can be used for NSCLC without adverse effects.
  
  
  CONCLUSIONS
  This case report suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SDT and TTF therapy, to be used in combination with serum GcMAF and colostrum MAF immunotherapy as a systemic treatment.
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan Kobe Saisei Mirai Clinic, Kobe, Japan Inui Immunotherapy Clinic, Osaka, Japan Tokyo Saisei Mirai Clinic, Tokyo, Japan contact@saisei-mirai.or.jp.
authors.forename: Toshio
authors.initials: T
authors.lastname: Inui
authors.affiliation: Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
authors.forename: Haruka
authors.initials: H
authors.lastname: Amitani
authors.affiliation: Saisei Mirai Cell Processing Center, Osaka, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kubo
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kuchiike
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Uto
authors.affiliation: Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan.
authors.forename: Takahito
authors.initials: T
authors.lastname: Nishikata
authors.affiliation: Inui Immunotherapy Clinic, Osaka, Japan contact@saisei-mirai.or.jp.
authors.forename: Martin
authors.initials: M
authors.lastname: Mette
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D016215:Macrophage-Activating Factors / Q000008:administration & dosage; D008297:Male; D000068437:Pemetrexed / Q000008:administration & dosage; D016896:Treatment Outcome; D014464:Ultrasonic Therapy; D014809:Vitamin D-Binding Protein / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D016215:Macrophage-Activating Factors; D014809:Vitamin D-Binding Protein; C101908:vitamin D-binding protein-macrophage activating factor; D000068437:Pemetrexed; D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine
keywords: GcMAF; Immunotherapy; colostrum MAF; macrophage activating factor (MAF); non-small cell lung cancer; ozone therapy; sonodynamic therapy (SDT); tumor treating field (TTF) therapy